Brief: Lipocine Provides Progress Update On LPCN 1154 Phase 3 Clinical
30/09/2025 14:54
Sept 30 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE PROVIDES PROGRESS UPDATE ON LPCN 1154 PHASE 3 CLINICAL TRIAL IN POSTPARTUM DEPRESSION (PPD) LIPOCINE INC: DSMB SAFETY REVIEW UPDATE PLANNED FOR 4Q 2025 LIPOCINE INC - TOPLINE RESULTS ANTICIPATED IN SECOND QUARTER OF 2026 Source text: ID:nPn2KqlDQa Further company coverage: LPCN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy